SCHEMBL4986144

SCHEMBL4986144

CCN(CC)C(=O)C(c1ccccc1)N(C)Cc1ccc2nc(C(N)=O)ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ GAA P10253 1/20 0.36
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ CHRM4 P08173 1/20 0.35
▸ CHRM5 P08912 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5666297 0.88 KLKB1 (0.37) MEN1KMT2ACYP2C19NPC1MAPT
SCHEMBL4986155 0.88 PLAU (0.40) MEN1KMT2ACYP2C9CYP2C19CHRM2
SCHEMBL4985651 0.80 MEN1 (0.41) MEN1KMT2AGAASMN1; SMN2KDM4E
SCHEMBL5664741 0.78 RAB9A (0.36) GAANPC1RAB9AOPRM1TMEM97
SCHEMBL5667134 0.74 OPRM1 (0.40) MEN1KMT2AMAPTCYP3A4HSD17B10
SCHEMBL13993524 0.72 MTTP (0.63) —
SCHEMBL5664866 0.72 KLKB1 (0.40) MEN1KMT2ALMNACYP3A4TSHR
SCHEMBL20921201 0.71 MEN1 (0.46) MEN1KMT2AGAANPC1LMNA
SCHEMBL4985659 0.67 MEN1 (0.42) MEN1KMT2ASMN1; SMN2
SCHEMBL5664748 0.67 BCHE (0.34) NPC1LMNARAB9ASMN1; SMN2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7393958-B2 Triamide-substituted heterobicyclic compounds PFIZER, INC. (US) 2008-07-01 — — US disclosed
US-7368573-B2 Triamide-substituted heterobicyclic compounds PFIZER INC. (US) 2008-05-06 — — US disclosed
US-20070093525-A1 Triamide-substituted heterobicyclic compounds PFIZER INC 2007-04-26 — — US disclosed
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS BERTINATO PETER 2006-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS APOB, MTPN, CTRB1 MEN1 1637/4885KMT2A 4384/4885GAA 671/4885
US-20070093525-A1 Triamide-substituted heterobicyclic compounds APOB, MTPN, CTRB1 MEN1 1637/4885KMT2A 4384/4885GAA 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback